Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Malignant Solid Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03878095
What this trial is testing

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Who this might be right for
Malignant Solid NeoplasmRefractory CholangiocarcinomaRefractory Malignant Solid Neoplasm
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390839
What this trial is testing

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+1 more
National Cancer Institute (NCI) 43
Early research (Phase 1)Ended earlyNCT05429502
What this trial is testing

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Who this might be right for
Neuroblastoma
Novartis Pharmaceuticals 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04266912
What this trial is testing

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
M.D. Anderson Cancer Center 23
Early research (Phase 1)Study completedNCT00303940
What this trial is testing

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsChildhood Germ Cell TumorKidney Cancer+5 more
National Institutes of Health Clinical Center (CC) 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT03213652
What this trial is testing

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Ependymoma+30 more
National Cancer Institute (NCI) 13
Early research (Phase 1)Temporarily pausedNCT04840589
What this trial is testing

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Platinum-Resistant Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 66
Testing effectiveness (Phase 2)Study completedNCT03253679
What this trial is testing

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Who this might be right for
Advanced Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Ended earlyNCT05551117
What this trial is testing

Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Who this might be right for
Castration-Resistant Prostatic CancerAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic Cancer+14 more
MacroGenics 192
Testing effectiveness (Phase 2)Study completedNCT00823524
What this trial is testing

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+6 more
Asan Medical Center 47
Early research (Phase 1)Study completedNCT00019630
What this trial is testing

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

Who this might be right for
Childhood Soft Tissue SarcomaChildhood Liver CancerBone Cancer+2 more
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT02408861
What this trial is testing

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmAnal CarcinomaHIV Infection+7 more
National Cancer Institute (NCI) 79
Early research (Phase 1)WithdrawnNCT04500548
What this trial is testing

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Who this might be right for
Constitutional Mismatch Repair Deficiency SyndromeHematopoietic and Lymphoid Cell NeoplasmLynch Syndrome+9 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT00931931
What this trial is testing

HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors

Who this might be right for
RhabdomyosarcomaOsteosarcomaEwing Sarcoma+6 more
Timothy Cripe 18
Testing effectiveness (Phase 2)Ended earlyNCT02440685
What this trial is testing

Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Who this might be right for
Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, Follicular+18 more
Asana BioSciences 51
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07819838
What this trial is testing

Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations

Who this might be right for
Recurrent Childhood Malignant Solid NeoplasmRecurrent Childhood NeuroblastomaRecurrent Childhood Rhabdomyosarcoma+3 more
Children's Oncology Group 77
Early research (Phase 1)WithdrawnNCT00458744
What this trial is testing

Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment

Who this might be right for
Brain and Central Nervous System TumorsLeukemiaLymphoma+1 more
Children's Oncology Group
Testing effectiveness (Phase 2)Active Not RecruitingNCT06357975
What this trial is testing

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 44
Early research (Phase 1)Study completedNCT03323034
What this trial is testing

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Who this might be right for
Recurrent LymphomaRecurrent Malignant Solid NeoplasmRecurrent Primary Central Nervous System Neoplasm+3 more
Children's Oncology Group 30
Early research (Phase 1)Study completedNCT05501821
What this trial is testing

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

Who this might be right for
Advanced Solid Tumor Malignancy
Kling Biotherapeutics B.V. 16
Next Page